GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Debt-to-EBITDA

Syncom Formulation (India) (NSE:SYNCOMF) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syncom Formulation (India)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Syncom Formulation (India)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Syncom Formulation (India)'s annualized EBITDA for the quarter that ended in Dec. 2023 was ₹476 Mil. Syncom Formulation (India)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Syncom Formulation (India)'s Debt-to-EBITDA or its related term are showing as below:

NSE:SYNCOMF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1   Med: 0.58   Max: 2.43
Current: 1.84

During the past 13 years, the highest Debt-to-EBITDA Ratio of Syncom Formulation (India) was 2.43. The lowest was 0.10. And the median was 0.58.

NSE:SYNCOMF's Debt-to-EBITDA is ranked worse than
52.97% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs NSE:SYNCOMF: 1.84

Syncom Formulation (India) Debt-to-EBITDA Historical Data

The historical data trend for Syncom Formulation (India)'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Debt-to-EBITDA Chart

Syncom Formulation (India) Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.10 1.38 1.81 2.43

Syncom Formulation (India) Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.62 - 1.93 -

Competitive Comparison of Syncom Formulation (India)'s Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Debt-to-EBITDA falls into.



Syncom Formulation (India) Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syncom Formulation (India)'s Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(831.815 + 0) / 343.012
=2.43

Syncom Formulation (India)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 475.544
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Syncom Formulation (India)  (NSE:SYNCOMF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Syncom Formulation (India) Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines